Lee Biosolutions: Renin Production
(PRLEAP.COM) St. Louis, Missouri – After a 10-year depletion of all known supplies of Renin, Lee Biosolutions has brought the enzyme up to current assay standards and geared up production on the marker that’s critical in hypertension research, among others.
Renin is an enzyme derived from human kidneys that plays a crucial role in cardiovascular research, both in terms of diagnostics and pharmaceuticals. This research is resulting in new classes of drugs to manage hypertension. In March 2005, Novartis Pharmaceuticals announced the first daily-dose rennin inhibitor to treat hypertension and improve organ protection.
Its potential reach, however, is much wider, and includes Cushing’s disease, Addison’s disease, and pituitary disease. Without Lee Biosolutions’ production of Renin, research would have been hindered as the previous supplies were depleted.
“The research is critical to many health issues we face,” said Lee. “Once the Renin was used up, researchers would have been forced to derive their own Renin as they needed it. That takes vital dollars away from the research itself. Our production of Renin allows that money to be spent where it’s needed – in developing accurate tests and effective treatments for these serious illnesses.”
For more information, please contact Burton Lee at 314-968-1091, or visit Lee Biosolutions online at www.leebio.com.


